• Vaccine Name: ALVAC-WNV-PrM/E (dogs and cats)
• Target Pathogen: West Nile virus
• Target Disease: West Nile fever
• Vaccine Ontology ID: VO_0004736
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• PrM gene engineering:
  • Type: Recombinant vector construction
  • Description: A canarypox vector expressing PrM and E genes (Karaca et al., 2005).
  • Detailed Gene Information: Click Here.
• E protein gene engineering:
  • Type: Recombinant vector construction
  • Description: A canarypox vector expressing PrM and E genes (Karaca et al., 2005).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001128
• Preparation: Canarypox vector expressing PrM and E genes of West Nile virus (WNV) (ALVAC-WNV) (Karaca et al., 2005).
• Immunization Route: Intramuscular injection (i.m.)

Dog Response

• Vaccination Protocol: One group of 17 dogs was vaccinated with 10^5.6 TCID 50 (Karaca et al., 2005).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: The animals were challenged 120 and 135 days after the second immunization, respectively via the bites of Aedes albopictus mosquitoes infected with WNV (Karaca et al., 2005).
• Efficacy: The first dose of vaccine induced a detectable antibody response in four dogs and five cats (one immunized with low and four with high doses). After the second dose, all the vaccinated dogs and all of the cats, immunized with high dose had detectable antibody titers, whereas only four of eight cats in the low dose group were seropositive. None of the vaccinated dogs and one vaccinated cat developed viremia following the WNV mosquito-challenge. In contrast, 14 of the 15 control dogs and 9 of the 11 control cats developed viremia (Karaca et al., 2005).

Cat Response

• Vaccination Protocol: Two groups of cats (groups 1 [n=14] vaccinated with 10^7.5 TCID(50) and 2 [n=8] 10^5.6 TCID(50)) were vaccinated twice at 28-day intervals (Karaca et al., 2005).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: The animals were challenged 120 and 135 days after the second immunization, respectively via the bites of Aedes albopictus mosquitoes infected with WNV (Karaca et al., 2005).
• Efficacy: The first dose of vaccine induced a detectable antibody response in four dogs and five cats (one immunized with low and four with high doses). After the second dose, all the vaccinated dogs and all of the cats, immunized with high dose had detectable antibody titers, whereas only four of eight cats in the low dose group were seropositive. None of the vaccinated dogs and one vaccinated cat developed viremia following the WNV mosquito-challenge. In contrast, 14 of the 15 control dogs and 9 of the 11 control cats developed viremia (Karaca et al., 2005).